PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin) and VABOMERE® (meropenem and vaborbactam), for use in pediatrics. In addition, Melinta and BARDA will partner on the development of BAXDELA® against biothreat pathogens. Under this contract, BARDA has awarded $20.5M for the base period, with the potential of additional funding of $121.4M, amounting to total funding up to $141.9M if all options are exercised. With this BARDA funding, Melinta aims to submit four supplemental New Drug Applications (sNDAs) for these new indications.
SINGAPORE, Sept. 20, 2022 /PRNewswire/ -- A. Menarini Asia-Pacific Holdings Pte. Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem® (meropenem and vaborbactam) in the People's Republic of China (China). This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enterobacterales (CRE). Currently, Vaborem® is being used to treat patients in the European Union for a variety of indications including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP) and is approved in the United States of America to treat cUTI.
Pomezia (Italy), July 9th, 2020 – Menarini Ricerche, the R&D division of the Menarini Group, announces that it has published four abstracts presenting the latest findings related to its meropenem/vaborbactam (Vaborem™) and delafloxacin (Quofenix™) clinical studies, confirming Menarini’s commitment to fighting life-threatening bacterial infections. The findings are included in the abstract book of the ECCMID, available at https://markterfolg.de/ESCMID/Abstractbook2020.pdf.
Rempex`s Vabomere (meropenem trihydrate, vaborbactam) Receives Approval in Europe
Medicines Co execs grab a $33M A round to spin out an infectious disease outfit with a pipeline
FLORENCE , Italy, October 11, 2018 / PRNewswire /Trade agreement expands the x istente and joint development for delafloxacin Consolidates the company's strategic objective on infectious diseases Menarini Group, an Italian biopharmaceutical company present in 136 countries around the world, and Melinta Therapeutics, a company based in the United States dedicated to the discovery, development and commercialization of new antibiotics to treat serious bacterial infections, announced an agreement according to which Menarini will acquire the exclusive rights to market meropenem / vaborbactam (Vabomere [TM] in the United States), oritavancin (Orbactiv ® ) and minocycline IV (Minocin IV ® ) in 68 countries in Europe, in Asia-Pacific including China , South Korea and Australia (excluding Japan), and in the Commonwealth of Independent States (CIS), including Russia.
FLORENCE , Italy, October 11, 2018 / PRNewswire /Trade agreement expands the x istente and joint development for delafloxacin Consolidates the company's strategic objective on infectious diseases Menarini Group, an Italian biopharmaceutical company present in 136 countries around the world, and Melinta Therapeutics, a company based in the United States dedicated to the discovery, development and commercialization of new antibiotics to treat serious bacterial infections, announced an agreement according to which Menarini will acquire the exclusive rights to market meropenem / vaborbactam (Vabomere [TM] in the United States), oritavancin (Orbactiv ® ) and minocycline IV (Minocin IV ® ) in 68 countries in Europe, in Asia-Pacific including China , South Korea and Australia (excluding Japan), and in the Commonwealth of Independent States (CIS), including Russia.
New medicine to treat infections in adults
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
Among the thirteen drugs recommended for approval are three orphan drugs, three Neulasta (pegfilgrastim) biosimilars, two anti-cancer drugs and a new antibiotic.